Trial Profile
A Multicenter, Placebo Controlled, 4-group Parallel Randomized, Double Blind, Phase II Study to Evaluate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2022
Price :
$35
*
At a glance
- Drugs Rebamipide mofetil (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Samjin Pharmaceutical Company
- 04 Mar 2022 Status changed from active, no longer recruiting to completed.
- 05 Nov 2018 New trial record